Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31539655 | 0.86 | TLR9 (0.33) | TSHRCYP1A2CYP2D6ALOX15MEN1 | |
| SCHEMBL25001356 | 0.82 | SIGMAR1 (0.41) | CYP1A2CYP2D6ALOX15 | |
| SCHEMBL24481344 | 0.82 | GBA1 (0.37) | TSHRCYP1A2CYP2D6ALOX15MEN1 | |
| SCHEMBL20323643 | 0.82 | ACHE (0.34) | TSHRALDH1A1 | |
| SCHEMBL24480647 | 0.81 | CYP1A2 (0.32) | TSHRCYP1A2CYP2D6ALOX15 | |
| SCHEMBL14996488 | 0.81 | NCF1 (0.43) | TSHRCYP1A2CYP2D6ALOX15 | |
| SCHEMBL24480557 | 0.81 | CYP1A2 (0.32) | TSHRCYP1A2CYP2D6ALOX15 | |
| SCHEMBL25856125 | 0.81 | TSHR (0.37) | TSHRCYP2D6 | |
| SCHEMBL29317070 | 0.80 | ACHE (0.35) | TSHR | |
| SCHEMBL24480642 | 0.78 | NCF1 (0.41) | TSHRCYP1A2CYP2D6ALOX15KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4397661-A1 | COMPOUND FOR DEGRADATION OF BCL-2 FAMILY PROTEINS AND MEDICAL APPLICATION THEREOF | Xizang Haisco Pharmaceutical Co., Ltd. (CN) | 2024-07-10 | — | — | EP | disclosed |
| WO-2023131167-A1 | COMPOUND FOR INHIBITING AND DEGRADING IRAK4, AND PHARMACEUTICAL COMPOSITION AND PHARMACEUTICAL APPLICATION THEREOF | 海思科医药集团股份有限公司 | 2023-07-13 | — | — | WO | disclosed |
| WO-2023083194-A1 | WEE1 PROTEIN KINASE DEGRADATION AGENT AND USE THEREOF | 杭州格博生物医药有限公司 | 2023-05-19 | — | — | WO | disclosed |
| WO-2023016518-A1 | HETEROCYCLIC DERIVATIVE, AND COMPOSITION AND PHARMACEUTICAL USE THEREOF | 四川海思科制药有限公司 | 2023-02-16 | — | — | WO | disclosed |